by Dennis Crouch
The chart below provides a small bit of information – the annual number of Federal Circuit decisions discussing the Doctrine of Equivalents.
- Pharma Tech v. Lifescan, Inc. 2019 WL 6222860 (Fed. Cir. Nov. 22, 2019) (prosecution history estoppel bars the claims for infringement under the doctrine of equivalents)
- Metricolor LLC v. L’Oreal S.A., 2019 WL 5588874 (Fed. Cir. Oct. 30, 2019) (granting plaintiff leave to amend complaint to add DOE allegation).
- UCP Intl. Co. Ltd. v. Balsam Brands Inc.,2019 WL 4955052 (Fed. Cir. Oct. 7, 2019) (vacating summary judgment of literal infringement and DOE based upon faulty claim construction).
- Eli Lilly and Co. v. Hospira, Inc., 933 F.3d 1320 (Fed. Cir. 2019) (narrowing amendment did not create prosecution history estoppel; no disclosure-dedication; district court did not err in finding insubstantial differences)
- Ajinomoto Co., Inc. v. Intl. Trade Commn., 932 F.3d 1342 (Fed. Cir. 2019) (affirming equivalents determination)
- VirnetX Inc. v. Apple Inc., 931 F.3d 1363 (Fed. Cir. 2019) (discussing the court’s prior reversal of a jury DOE verdict)
- Amgen Inc. v. Coherus BioSciences Inc., 931 F.3d 1154 (Fed. Cir. 2019) (prosecution history estoppel barred patentees claiming doctrine of equivalents infringement)
See John R. Allison & Mark A. Lemley, The (Unnoticed) Demise of the Doctrine of Equivalents, 59 Stan. L. Rev. 955 (2007) (DOE used to be important, but not anymore); Lee Petherbridge, On the Decline of the Doctrine of Equivalents, 31 Cardozo L. Rev. 1371 (2010) (confirming the demise and remarking that the result “is the culmination of a concerted and prolonged court-driven effort to make [DOE’s] favorable application the exception, not the rule.”); and David L. Schwartz, Explaining the Demise of the Doctrine of Equivalents, 26 Berkeley Tech. L.J. 1157, 1159 (2011).